** Shares of healthcare company Allurion Technologies
** Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and lean body mass increase to 68.5%
** Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption
** The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR
** Company says all 52 patients remained adherent to the GLP-1 medication through eight months
** Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company
** Stock had fallen 88.5% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。